Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Goh

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Oncogene|December 1, 1993
Molecular characterization of a variant Ph1 translocation t(9;22;11) (q34;q11;q13) in chronic myelogenous leukemia (CML) reveals the translocation of the 3'-part of BCR gene to the chromosome band 11q13P R Koduru, J C Goh, R G Pergolizzi, et al.
Calcified Tissue International|January 1, 1995
Effect of decalcification on bone mineral content and bending strength of feline femurK M Shah, J C Goh, R Karunanithy, et al.
Clinical Orthopaedics and Related Research|June 1, 1992
Biomechanical study on the load-bearing characteristics of the fibula and the effects of fibular resectionJ C Goh, A M Mech, E H Lee, et al.
American Journal of Hematology|October 1, 1993
Phenotypic and genotypic characterization of Hodgkin's diseaseP R Koduru, M Susin, P Schulman, et al.
Hematologic Pathology|January 1, 1991
Different patterns of chromosome and molecular breakage in classic Ph1 chronic myelogenous leukemia (CML) and variant Ph1 CMLP Koduru, J C Goh, S L Allen, et al.
British Journal of Haematology|November 1, 1993
Serial phenotypic, cytogenetic and molecular genetic studies in Richter's syndrome: demonstration of lymphoma development from the chronic lymphocytic leukaemia cellsP R Koduru, S M Lichtman, T F Smilari, et al.
Journal for Immunotherapy of Cancer|June 23, 2016
Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trialH J Gray, B Benigno, J Berek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 studyC Gratzke, M Özgüroğlu, A Peer, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Oncogene|December 1, 1993
Molecular characterization of a variant Ph1 translocation t(9;22;11) (q34;q11;q13) in chronic myelogenous leukemia (CML) reveals the translocation of the 3'-part of BCR gene to the chromosome band 11q13P R Koduru, J C Goh, R G Pergolizzi, et al.
Calcified Tissue International|January 1, 1995
Effect of decalcification on bone mineral content and bending strength of feline femurK M Shah, J C Goh, R Karunanithy, et al.
Clinical Orthopaedics and Related Research|June 1, 1992
Biomechanical study on the load-bearing characteristics of the fibula and the effects of fibular resectionJ C Goh, A M Mech, E H Lee, et al.
American Journal of Hematology|October 1, 1993
Phenotypic and genotypic characterization of Hodgkin's diseaseP R Koduru, M Susin, P Schulman, et al.
Hematologic Pathology|January 1, 1991
Different patterns of chromosome and molecular breakage in classic Ph1 chronic myelogenous leukemia (CML) and variant Ph1 CMLP Koduru, J C Goh, S L Allen, et al.
British Journal of Haematology|November 1, 1993
Serial phenotypic, cytogenetic and molecular genetic studies in Richter's syndrome: demonstration of lymphoma development from the chronic lymphocytic leukaemia cellsP R Koduru, S M Lichtman, T F Smilari, et al.
Journal for Immunotherapy of Cancer|June 23, 2016
Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trialH J Gray, B Benigno, J Berek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 studyC Gratzke, M Özgüroğlu, A Peer, et al.
Pageof 5